Maxim Group reaffirmed their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS) in a report released on Friday morning, AnalystRatings.com reports. Maxim Group currently has a $11.00 target price on the stock.
“Sensus reported lower-than-expected 1Q19 revenue and a wider-than- expected GAAP EPS loss due to a delayed shipment of seven SRT-100 Vision systems to its largest customer. We are slightly reducing our estimates to reflect the miss and a lower 2019 growth rate.”,” the firm’s analyst commented.
Other equities research analysts have also issued reports about the company. Alliance Global Partners lowered Sensus Healthcare from a buy rating to a neutral rating in a research report on Friday. ValuEngine lowered Sensus Healthcare from a buy rating to a hold rating in a research report on Wednesday, May 1st. Northland Securities reiterated a sell rating and issued a $5.00 price objective on shares of Sensus Healthcare in a research report on Friday, February 15th. Roth Capital restated a buy rating on shares of Sensus Healthcare in a research report on Tuesday, February 19th. Finally, TheStreet upgraded Sensus Healthcare from a d rating to a c rating in a research report on Thursday, February 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $10.32.
Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.11). The business had revenue of $5.44 million during the quarter, compared to the consensus estimate of $7.81 million. Sensus Healthcare had a negative return on equity of 14.30% and a negative net margin of 11.65%. On average, equities research analysts anticipate that Sensus Healthcare will post 0.02 earnings per share for the current year.
In related news, EVP Richard Golin sold 5,943 shares of Sensus Healthcare stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $7.56, for a total transaction of $44,929.08. Following the sale, the executive vice president now directly owns 925,237 shares in the company, valued at $6,994,791.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 7,203 shares of company stock worth $54,379 over the last 90 days. 41.10% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SRTS. Vanguard Group Inc boosted its position in shares of Sensus Healthcare by 48.2% during the third quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sensus Healthcare by 48.2% during the third quarter. Vanguard Group Inc. now owns 305,833 shares of the company’s stock valued at $2,563,000 after purchasing an additional 99,444 shares in the last quarter. Garrison Bradford & Associates Inc. boosted its position in shares of Sensus Healthcare by 275.1% during the first quarter. Garrison Bradford & Associates Inc. now owns 108,400 shares of the company’s stock valued at $761,000 after purchasing an additional 79,500 shares in the last quarter. BlackRock Inc. boosted its position in shares of Sensus Healthcare by 182.9% during the first quarter. BlackRock Inc. now owns 73,653 shares of the company’s stock valued at $517,000 after purchasing an additional 47,622 shares in the last quarter. Finally, B. Riley Financial Inc. bought a new stake in shares of Sensus Healthcare during the first quarter valued at approximately $281,000. Institutional investors own 6.51% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Story: Lock-Up Period Expiration
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.